Management of Doxazosin Therapy in End‑Stage Renal Disease (ESRD) Patients
Role of Alpha‑Blockers in ESRD Hypertension
- Alpha‑1 blockers such as doxazosin are classified as secondary antihypertensive agents but remain viable options for dialysis patients when first‑line drugs are ineffective or not tolerated; the 2017 ACC/AHA hypertension guideline cites their use despite a higher risk of orthostatic hypotension, especially in older adults, and recommends them as second‑line therapy when benign prostatic hyperplasia (BPH) is present. Strong recommendation. 1
- In elderly ESRD patients, alpha‑blockers increase the risk of orthostatic and intradialytic hypotension; therefore, regular supine‑and‑standing blood‑pressure checks are advised, and the dual benefit for BPH should be considered when selecting therapy. Moderate recommendation. [2][3]
Indications for Switching or Adding Alternative Agents
- If heart failure with reduced ejection fraction (HFrEF) develops, guidelines from the American Heart Association advise adding or substituting a beta‑blocker (carvedilol, metoprolol succinate, or bisoprolol) together with an ACE inhibitor or ARB; doxazosin should be reduced or discontinued. Strong recommendation. 4
- For patients with diabetes and albuminuria, renal‑protective therapy with an ACE inhibitor or ARB is prioritized over alpha‑blockade, reflecting evidence that these agents reduce proteinuria and slow CKD progression. Strong recommendation. [5][6]
- In the presence of coronary artery disease or prior myocardial infarction, beta‑blockers are preferred to mitigate ischemic risk, and doxazosin may be retained only if additional indications (e.g., BPH) exist. Strong recommendation. [7][8]
Blood‑Pressure Targets and Treatment Algorithm
- The target blood pressure for most ESRD patients on dialysis is <130/80 mmHg; if this target is not achieved despite optimal volume control and doxazosin therapy, the preferred approach is to add an ACE inhibitor, ARB, or calcium‑channel blocker rather than replace doxazosin. Strong recommendation. [8][9]
- The Kidney Disease Outcomes Quality Initiative (K/DOQI) recommends ACE inhibitors or ARBs as the first‑line add‑on agents for dialysis patients, followed by calcium‑channel blockers or beta‑blockers if further control is needed. Strong recommendation. 8
- Prior to intensifying pharmacotherapy, clinicians should optimize volume status by achieving dry weight and enforcing sodium restriction, as inadequate volume control is the most common cause of resistant hypertension in ESRD. Strong recommendation. 9
Monitoring and Safety Considerations
- Routine assessment for orthostatic symptoms or intradialytic hypotension is essential when using doxazosin, given its propensity to cause blood‑pressure drops upon standing, especially in older dialysis patients. Moderate recommendation. 1
- The principle “if it isn’t broken, don’t fix it” is supported by hypertension literature, emphasizing that switching a well‑tolerated antihypertensive without a clear clinical indication can jeopardize blood‑pressure stability and adherence. Moderate recommendation. 10
All facts are derived from cited sources and reflect the strength of evidence as indicated in the original guidelines or studies.